CN102321584B - 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 - Google Patents

预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 Download PDF

Info

Publication number
CN102321584B
CN102321584B CN201110195193.7A CN201110195193A CN102321584B CN 102321584 B CN102321584 B CN 102321584B CN 201110195193 A CN201110195193 A CN 201110195193A CN 102321584 B CN102321584 B CN 102321584B
Authority
CN
China
Prior art keywords
gene
cell
seq
expression
ovarian cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201110195193.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102321584A (zh
Inventor
萨默.阿尔-穆拉尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Original Assignee
Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Research Foundation filed Critical Penn State Research Foundation
Publication of CN102321584A publication Critical patent/CN102321584A/zh
Application granted granted Critical
Publication of CN102321584B publication Critical patent/CN102321584B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201110195193.7A 2003-12-31 2004-12-30 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 Expired - Fee Related CN102321584B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53350503P 2003-12-31 2003-12-31
US60/533,505 2003-12-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2004800421486A Division CN1922332B (zh) 2003-12-31 2004-12-30 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法

Publications (2)

Publication Number Publication Date
CN102321584A CN102321584A (zh) 2012-01-18
CN102321584B true CN102321584B (zh) 2014-01-08

Family

ID=34748910

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201110195193.7A Expired - Fee Related CN102321584B (zh) 2003-12-31 2004-12-30 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
CN201210472073.1A Expired - Fee Related CN102989009B (zh) 2003-12-31 2004-12-30 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
CN2004800421486A Expired - Fee Related CN1922332B (zh) 2003-12-31 2004-12-30 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201210472073.1A Expired - Fee Related CN102989009B (zh) 2003-12-31 2004-12-30 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
CN2004800421486A Expired - Fee Related CN1922332B (zh) 2003-12-31 2004-12-30 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法

Country Status (7)

Country Link
US (5) US7700280B2 (https=)
EP (2) EP1704250B1 (https=)
JP (3) JP4682152B2 (https=)
CN (3) CN102321584B (https=)
ES (1) ES2394799T3 (https=)
TW (1) TWI301066B (https=)
WO (1) WO2005066371A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102321584B (zh) * 2003-12-31 2014-01-08 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
EP3327031A1 (en) * 2004-05-14 2018-05-30 Abraxis BioScience, LLC Disease site-delivering pharmaceutical compositions comprising paclitaxel
AU2006249235B2 (en) * 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US7553496B2 (en) * 2004-12-21 2009-06-30 University Of Kentucky Research Foundation VEGF-A as an inhibitor of angiogenesis and methods of using same
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
CN101365806B (zh) * 2005-12-01 2016-11-16 医学预后研究所 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途
CA2651846C (en) * 2006-06-13 2019-11-12 The Rockefeller University Use of p11 to diagnose a p11/5-ht related disorder
DE102006035393A1 (de) * 2006-11-02 2008-05-15 Signature Diagnostics Ag Prognostische Marker für die Klassifizierung des dreijährigen progessionsfreien Überlebens von Patienten mit Kolonkarzinomen basierend auf Expressionsprofilen von biologischen Proben
US20110178154A1 (en) * 2007-02-06 2011-07-21 Birrer Michael J gene expression profile that predicts ovarian cancer subject response to chemotherapy
WO2008109519A2 (en) * 2007-03-02 2008-09-12 University Of South Florida Micro-rna profiles associated with endometrial cancer development and response to cisplatin and doxorubicin chemotherapy
US8034792B2 (en) 2007-09-11 2011-10-11 University Of Massachusetts Insulin-like growth factor binding protein 7 for treatment of cancer
JP5461201B2 (ja) * 2008-01-31 2014-04-02 学校法人慶應義塾 抗がん剤感受性の判定方法
US8093000B2 (en) * 2008-05-09 2012-01-10 The Regents Of The University Of California Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation
WO2010135786A1 (en) * 2009-05-29 2010-12-02 Clinical Genomics Pty. Ltd. A method for diagnosing neoplasms and molecules for use therein
CN102625839A (zh) * 2009-07-09 2012-08-01 阿布拉西斯生物科学有限责任公司 Sparc反义组合物和其用途
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
KR20120092597A (ko) * 2009-09-18 2012-08-21 아브락시스 바이오사이언스, 엘엘씨 암 치료에 있어 ｓｐａｒｃ 미세환경 시그니처의 용도
US8765713B2 (en) 2009-10-30 2014-07-01 Keio University Method for determination of sensitivity to anti-cancer agent
CA2800557A1 (en) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
DK2576638T3 (da) 2010-05-25 2021-03-15 Syndevrx Inc Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf
CA2801190A1 (en) 2010-06-03 2011-12-08 Abraxis Bioscience, Llc Use of the sparc microenvironment signature in the treatment of cancer
WO2012110425A1 (en) * 2011-02-14 2012-08-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for monitoring the response to treatment and for treating colorectal cancer
BR112013031019A2 (pt) * 2011-06-02 2017-03-21 Almac Diagnostics Ltd teste diagnóstico molecular para câncer
US9409978B2 (en) * 2011-09-09 2016-08-09 University Of Massachusetts Modulation of midbody derivatives
MX2015006955A (es) 2012-12-03 2016-01-25 Almac Diagnostics Ltd Prueba de diagnostico molecular para cancer.
CN105431426A (zh) 2013-04-10 2016-03-23 新德发制药有限公司 Metap2抑制剂和治疗肥胖症的方法
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
CN103893763B (zh) * 2014-04-10 2016-05-11 武汉大学 Vinexin-β基因在心肌梗死中的应用
CA2955914C (en) * 2014-07-21 2022-09-06 Ignacio Canals Almazan Tungsten (vi) salts for use thereof in the treatment of infertility, for favoring normal reproduction and fertility in a non-diabetic female mammal, as well as for improving the efficacy of assisted reproductive techniques
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
US9969722B2 (en) 2015-12-10 2018-05-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
CN108697807B (zh) * 2016-01-11 2021-11-26 辛德弗雷克斯公司 代谢功能障碍引起的肿瘤的治疗
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
EP3714896A4 (en) * 2017-11-21 2021-08-04 Miwa, Naofumi MEANS FOR INHIBITING METASTASISATION OF HUMAN CANCER CELLS AND MEANS FOR DETERMINING HUMAN CANCER CELLS
CN113196055B (zh) 2018-10-15 2025-06-27 马克斯·普朗克科学促进协会 用于治疗疾病的化合物及其筛选方法
CN113453721B (zh) 2018-10-26 2025-09-16 辛德弗雷克斯公司 Metap2抑制剂的生物标志物及其应用
CA3127237A1 (en) 2019-02-08 2020-08-13 Dewpoint Therapeutics, Inc. Methods of characterizing condensate-associated characteristics of compounds and uses thereof
CA3140651A1 (en) * 2019-05-15 2020-11-19 Whitehead Institute For Biomedical Research Methods of characterizing and utilizing agent-condensate interactions
CN110331203B (zh) * 2019-07-30 2023-04-18 中南大学湘雅三医院 泛素连接酶chaf1b作为靶位点在制备肺腺癌顺铂增敏药物中的应用
KR20220084047A (ko) 2019-09-18 2022-06-21 듀포인트 테라퓨틱스, 인크. 응축물 관련 특이성에 대한 스크리닝 방법 및 이의 용도
EP4329778A4 (en) * 2021-04-26 2025-02-19 Crititech, Inc. CISPLATIN PARTICLES AND THEIR USES
WO2023196540A1 (en) * 2022-04-06 2023-10-12 Vanderbilt University Articles and methods for inhibiting methionine aminopeptidase activity
WO2025057928A1 (ja) * 2023-09-11 2025-03-20 国立大学法人大阪大学 細胞外小胞内ｒｎａ修飾による卵巣癌プラチナ製剤抵抗性を判別するための検査方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5902880A (en) * 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US6146886A (en) * 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
CA2207593A1 (en) 1994-12-13 1996-06-20 John Gustofson Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
CA2301166A1 (en) 1997-07-24 1999-02-04 Yuan-Peng Zhang Liposomal compositions for the delivery of nucleic acid catalysts
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
JP2003528024A (ja) 1997-12-16 2003-09-24 バレンティス・インコーポレーテッド 製剤化された核酸分子の無針注入
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
EP1208191A4 (en) * 1999-08-13 2003-12-10 Human Genome Sciences Inc 13 HUMANE COLONAL AND COLONAL CANCER-ASSOCIATED PROTEINS
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
WO2001061048A2 (en) * 2000-02-17 2001-08-23 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification, assessment, prevention and therapy of human cancers
US7279294B2 (en) * 2000-04-03 2007-10-09 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih Tumor markers in ovarian cancer
US20020137663A1 (en) 2000-08-11 2002-09-26 Forman Barry M. The anti-neoplastic agent ET-743 inhibits trans activation by SXR
ATE365922T1 (de) * 2000-10-27 2007-07-15 Mount Sinai Hospital Corp Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
WO2002046765A2 (en) * 2000-11-08 2002-06-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US7195868B2 (en) * 2001-04-18 2007-03-27 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention, and therapy of human cancers
EP1451343B1 (en) * 2001-11-02 2012-10-17 Dana-Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof
AU2002357017A1 (en) * 2001-11-28 2003-06-10 Mediomics, Llc Anti-angiogenesis methods, compositions and uses therefor
WO2003078603A2 (en) * 2002-03-15 2003-09-25 Board Of Regents, The University Of Texas System Strong gene sets for glioma classification
US20040097452A1 (en) * 2002-11-19 2004-05-20 Isis Pharmaceuticals Inc. Modulation of kallikrein 6 expression
CN102321584B (zh) * 2003-12-31 2014-01-08 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
WO2006044017A2 (en) * 2004-08-13 2006-04-27 Jaguar Bioscience Inc. Systems and methods for identifying diagnostic indicators

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Analysis of molecular profile data using generative and discriminative methods;E.J.Moler et al.;《Physiological Genomics》;20000101;第4卷;109-126 *
E.J.Moler et al..Analysis of molecular profile data using generative and discriminative methods.《Physiological Genomics》.2000,第4卷109-126.
Lu PY et al..siRNA-mediated antitumorigenesis for drug target validation and therapeutics.《Europe PubMed Central》.2003,第5卷(第3期),225-234.
siRNA-mediated antitumorigenesis for drug target validation and therapeutics;Lu PY et al.;《Europe PubMed Central》;20030630;第5卷(第3期);225-234 *

Also Published As

Publication number Publication date
US20100221731A1 (en) 2010-09-02
ES2394799T3 (es) 2013-02-05
CN102989009A (zh) 2013-03-27
EP2395112B1 (en) 2017-02-15
CN1922332B (zh) 2013-06-12
US7700280B2 (en) 2010-04-20
EP1704250A2 (en) 2006-09-27
CN1922332A (zh) 2007-02-28
US20100221729A1 (en) 2010-09-02
JP5789591B2 (ja) 2015-10-07
JP2010209076A (ja) 2010-09-24
JP5285012B2 (ja) 2013-09-11
TWI301066B (en) 2008-09-21
JP2007517058A (ja) 2007-06-28
CN102321584A (zh) 2012-01-18
JP2013079261A (ja) 2013-05-02
US20050176669A1 (en) 2005-08-11
WO2005066371A3 (en) 2006-04-20
JP4682152B2 (ja) 2011-05-11
EP2395112A1 (en) 2011-12-14
EP1704250B1 (en) 2012-09-19
WO2005066371A2 (en) 2005-07-21
CN102989009B (zh) 2015-06-03
TW200531682A (en) 2005-10-01
US20100221730A1 (en) 2010-09-02
US8192935B2 (en) 2012-06-05
US20160348180A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
CN102321584B (zh) 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
Ernst et al. Genomic and expression profiling of glioblastoma stem cell–like spheroid cultures identifies novel tumor-relevant genes associated with survival
Purow et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation
Zhou et al. The chemokine GRO-α (CXCL1) confers increased tumorigenicity to glioma cells
Diazzi et al. Blockade of the pro‐fibrotic reaction mediated by the miR‐143/‐145 cluster enhances the responses to targeted therapy in melanoma
Dou et al. Aberrant overexpression of ADAR1 promotes gastric cancer progression by activating mTOR/p70S6K signaling
CN107435074A (zh) Ces8基因在肾透明细胞癌诊疗中的应用
US8236772B2 (en) Methods of modulating angiogenesis and screening compounds for activity in modulating angiogenesis
Hou et al. GRIK1 promotes glioblastoma malignancy and is a novel prognostic factor of poor prognosis
US10961589B2 (en) HER2-regulated RNA as a diagnostic and therapeutic targets in HER2+ breast cancer
Lu et al. Downregulation of long non-coding RNA LINP1 inhibits the malignant progression of esophageal squamous cell carcinoma
Liu et al. Circular RNA expression profile identifies circMGEA5 as a novel metastasis‐promoting factor and potential biomarker in osteosarcoma
CN119082310B (zh) Aml诊断和预后预测相关的生物标志物及其应用
CN114854856B (zh) Arpc1b基因的相关用途及药物
CN108165624A (zh) 生物标志物在骨肉瘤诊治中的应用
CN107893119A (zh) Zcchc12在骨肉瘤中的应用
CN107385081A (zh) 一种与肾癌相关的基因及其应用
CN118272447A (zh) 一种利用1l1rap调节aml细胞耐药性的方法
CN116515989A (zh) 生物标志物在诊治sah脑血管痉挛中的应用
CN117947158A (zh) 用作预测结直肠癌氟尿嘧啶治疗敏感性的标志物mlck1
CN119410776A (zh) 外泌体miR-211-3p在预防和/或治疗卵巢癌腹膜转移中的应用
CN107988374A (zh) 一种与骨肉瘤相关的分子标志物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140108

Termination date: 20201230